№ files_lp_4_process_3_087876
File format: docx Character count: 1618 File size: 20 KB
Supplementary research table listing genes with the highest positive and negative log2 fold changes in two treatment comparisons relative to untreated samples.
Type of document: Supplementary table
Scientific field: Molecular biology
Research area: Gene expression analysis
Data type: Differential gene expression results
Comparison groups: Losartan+FFX+CRT versus untreated; FFX+CRT versus untreated
Measured variable: log2FoldChange
Number of upregulated genes listed: 30 per comparison
Number of downregulated genes listed: 30 per comparison
Biological entities: Human genes
Content structure: Gene names with corresponding log2FoldChange values
Context of study: Treatment-associated transcriptional changes
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Supplementary Note: Synaptic and Transcriptionally Downregulated Genes Associated with Cortical Thickness Differences in Children with Autism
Authors: Romero-Garcia, R.; Warrier, V.; Bullmore, E.T.; Baron-Cohen, S.; Bethlehem, R.A.I.
Type of document: Supplementary scientific note
Field: Neuroimaging and transcriptomics
Research focus: Cortical thickness differences in autism and ADHD
Data sources: ABIDE; ADHD-200; Allen Institute for Brain Science gene expression dataset
Study population: Male children aged 8–12 years
Discovery sample size: 218 subjects
Validation datasets: ABIDE II (Georgetown University; Kennedy Krieger Institute)
Gene expression source: Post-mortem adult human brain samples (n=6 donors)
Methods: Structural MRI (T1-weighted MPRAGE); Freesurfer v5.3 processing; Partial Least Squares Regression; pathway and enrichment analyses
Brain parcellation: 308 cortical regions based on Desikan-Killiany atlas
Comparative groups: Autism; ADHD; neurotypical controls
Statistical procedures: Cross-validation; regression analyses; batch correction using ComBat
Associated analyses: KEGG pathway analysis; gene co-expression modules; rare and common genetic variant enrichment
References included: Yes
A phase II trial of Bendamustine, Rituximab and Acalabrutinib in previously untreated Waldenström’s Macroglobulinemia (BRAWM)
Year: 2024
Country: Canada
Study Type: Phase II clinical trial
Treatment Regimen: Bendamustine-Rituximab combination with concurrent Acalabrutinib
Participants: 62
Centers: 9
Primary Endpoint: Combined Complete and Very Good Partial Response (CR+VGPR) rates
Secondary Endpoints: Best overall response (BoR), progression-free survival (PFS), overall survival (OS), duration of response (DoR), Minimal Residual Disease (MRD)
Median Age: 69
Mutation Analysis: MYD88 89.3%, CXCR4 28.6%, TP53 1.8%
Adverse Events: Treatment-related adverse events (TRAEs) in 53 participants, 42 Grade 3/4 during combination therapy, 15 Grade 3/4 during monotherapy
Follow-up: Median 350 days
Data Cut-off: June 5, 2024
Document Type: Clinical trial report
Purpose of resubmission The standard re-entry resubmission requested an Authority Required General Schedule listing of acalabrutinib, for use in combination with obinutuzumab, for the treatment of patients with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), who are considered unsuitable for treatment with fludarabine-based chemoimmunotherapy.
Year: 2023
Region / city: Australia
Topic: Oncology, Pharmaceuticals
Document Type: Resubmission
Institution: Australian Government, Pharmaceutical Benefits Advisory Committee
Author: AstraZeneca Pty Ltd.
Target Audience: Healthcare professionals, regulatory bodies
Effective Period: Ongoing
Approval Date: November 2021
Date of Changes: November 2021
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]
Year: 2025
Organization: NICE Technology Appraisal Committee
Document type: Interests Register
Region: United Kingdom
Subject: Conflicts of interest in health technology appraisal
Participants: Peter Wheatley Price, Warren Linley, David McAllister, Professor Suneil Jain, Rhiannon Owen, Holly Knight
Date of publication: TBC
Relevant period: 2025
Financial interests: Pfizer, AstraZeneca, Bayer, Astellas, Johnson & Johnson, Boston Scientific, Teleflex, Accord, Molli Surgical, BXT Nanotherapy
Professional roles: Committee members, clinical expert, patient expert
Access to trial data: Yes
Appraisal ID: 4004
Record type: Committee disclosures
Cohort Characteristics of 147 Patients with Previously Untreated Small Cell Carcinoma of the Esophagus
Year of diagnosis: Prior to 2015–2019
Number of patients: 147
Sex distribution: 109 male, 38 female
Age distribution: ≤60 years: 73, >60 years: 74
Alcohol abuse: Yes: 71, No: 76
Tobacco abuse: Yes: 97, No: 50
Smoking index: ≤400: 93, >400: 54
BMI distribution: <25: 108, 25–29.9: 39
Family history of cancer: Yes: 32, No: 115
Treatment modality: Surgery alone: 48, Surgery with adjuvant therapy: 99
Tumor location: Upper: 17, Middle: 111, Lower: 19
Tumor length: <5 cm: 89, ≥5 cm: 58
Macroscopic tumor type: Superficial: 22, Protruded: 11, Medullary: 48, Mushroom: 36, Ulcerative: 19, Intracavity: 11
Histological components: Pure small cell: 116, Mixed small cell: 31
T stage: T1: 45, T2: 39, T3: 59, T4: 4
N stage: N0: 50, N1: 53, N2: 32, N3: 12
TNM stage: I: 29, II: 49, III: 69
PD-L1 expression in tumor cells (TCs): <1%: 147, ≥1%: 0
PD-L1 expression in tumor-infiltrating immune cells (TIICs): <1%: 82, ≥1%: 65
PD-L1 expression by CPS: <1: 105, ≥1: 42
CD8 density/mm²: Median 111.1, Range 7.5–1458.6
Abbreviations: BMI: body mass index; TCs: tumor cells; TIICs: tumor-infiltrating immune cells; CPS: combined positive score
Topics: Upregulated Downregulated untreated